Alethea Capital Management’s AstraZeneca AZN Stock Holding History

Alethea Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,950	Closed	-$890K	–	88
2021 Q1	$890K	Buy	+8,950	New	+$900K	0.54%	22
2020 Q4	–	Sell	-9,691	Closed	-$1.06M	–	75
2020 Q3	$1.06M	Buy	+9,691	New	+$1.08M	0.72%	17
2019 Q2	–	Sell	-12,037	Closed	-$973K	–	84
2019 Q1	$973K	Buy	+12,037	New	+$949K	0.69%	21
2018 Q4	–	Sell	-9,784	Closed	-$774K	–	65
2018 Q3	$774K	Buy	+9,784	New	+$740K	1.16%	19

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Alethea Capital Management's AZN Position: Q2 2021 in Review

Alethea Capital Management sold out of AstraZeneca (AZN) in Q2 2021, closing a stake of 8,950 shares — an estimated $890K sold.

Alethea Capital Management first reported a position in AZN in Q3 2018 and held it in 4 quarters. The position peaked at $1.06M in Q3 2020. 771 funds tracked by Wall St. Rank hold AZN as of Q2 2021.

Alethea Capital Management reported no remaining AstraZeneca position as of Q2 2021 after selling out during the quarter.
Alethea Capital Management sold 8,950 AstraZeneca shares in Q2 2021, an estimated $890K.
Alethea Capital Management first reported a position in AstraZeneca in Q3 2018 and held it in 4 quarters.
Alethea Capital Management's AstraZeneca position peaked at $1.06M in Q3 2020.
771 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2021.

Based on Alethea Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.